Evidence map›Paper›PMID 31707428›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2020

Variations in radioiodine ablation: decision-making after total thyroidectomy.

O Maas, F Forrer, M Maas, C M Panje, J Blautzik, M Brühlmeier, I Engel-Bicik, L Giovanella, A Haldemann, M E Kamel and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

O MaasDepartment of Radiology and Nuclear Medicine, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland. olechristopher.maas@kssg.ch.ORCID 0000-0002-9121-6143
F ForrerDepartment of Radiology and Nuclear Medicine, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland.
M MaasDepartment of Radiology and Nuclear Medicine, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland.
C M PanjeDepartment of Radiation Oncology, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland.
J BlautzikDepartment of Radiology and Nuclear Medicine, Hislanden Klinik St. Anna, St. Anna-Strasse 32, 6006, Luzern, Switzerland.
M BrühlmeierNuclear Medicine and PET-Centre, Kantonsspital Aarau, Tellstrasse 25, 5001, Aarau, Switzerland.
I Engel-BicikDepartment of Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
L GiovanellaDepartment of Nuclear Medicine and PET-Centre, Regional Hospital Lugano and Bellinzona, Via Officina 3, 6500, Bellinzona, Switzerland.
A HaldemannDepartment of Radiology and Nuclear Medicine, Stadtspital Triemli, Birmensdorferstrasse 497, 8063, Zurich, Switzerland.
M E KamelDepartment of Nuclear Medicine, Hôpital du Valais, Av. Grand-Champsec 80, 1951, Sion, Switzerland.
S KneifelDepartment of Nuclear Medicine, Cantonal Hospital Graubünden Chur, Loëstrasse 170, 7000, Chur, Switzerland.
C RottenburgerDepartment of Radiology and Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland.
N SchaeferDepartment of Nuclear Medicine, University Hospital Lausanne, Rue de Bugnon 46, 1011, Lausanne, Switzerland.
M A WalterDepartment of Nuclear Medicine, University Hospital Geneva, Rue Gabrielle-Perret-Gentil 4, 1205, Geneva, Switzerland.
S WeidnerDepartment of Nuclear Medicine, Inselspital Bern, Freiburgstrasse 18, 3010, Bern, Switzerland.
P M PutoraDepartment of Radiation Oncology, Kantonsspital St. Gallen, Rorschacherstrasse 95, 9007, St. Gallen, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe role of radioiodine treatment following total thyroidectomy for differentiated thyroid cancer is changing. The last major revision of the American Thyroid Association (ATA) Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer in 2015 changed treatment recommendations dramatically in comparison with the European Association of Nuclear Medicine (EANM) 2008 guidelines. We hypothesised that there is marked variability between the different treatment regimens used today.

methodsWe analysed decision-making in all Swiss hospitals offering radioiodine treatment to map current practice within the community and identify consensus and discrepancies. RESULTS AND

conclusionWe demonstrated that for low-risk DTC patients after thyroidectomy, some institutions offered only follow-up, while RIT with significant activities is recommended in others. For intermediate- and high-risk patients, radioiodine treatment is generally recommended. Dosing and treatment preparation (recombinant human thyroid stimulation hormone (rhTSH) vs. thyroid hormone withdrawal (THW)) vary significantly among centres.

Indexed as

Thyroid NeoplasmsThyroid NoduleHumansIodine RadioisotopesThyroidectomyTreatment OutcomeIodine RadioisotopesDecision MakingRadioiodineThyroidectomyTreatment

Identifiers

PMID31707428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.